Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results